Skip to main content
. 2024 Dec 15;16(12):4675–4684. doi: 10.4251/wjgo.v16.i12.4675

Figure 1.

Figure 1

Overall survival. A: Overall survival (OS) in patients with gastroenteropancreatic neuroendocrine tumors; B: OS according to primary tumor; C: Progression-free survival based on primary tumor.